Is Berkshire The Best Stock to Buy in a Bad Market?
Berkshire Hathaway (NYSE:BRK.A, BRK.B) has historically been one of the…
Sell
43
OMEX Quote, Financials, Valuation and Earnings
Last price:
$1.17
Seasonality move
:
1.63%
Day range:
$1.09 - $1.31
52-week range:
$0.27 - $5.57
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
43.25x
P/B ratio:
--
Volume:
8.6M
Avg. volume:
34.7M
1-year change:
-66.3%
Market cap:
$35.9M
Revenue:
$768.7K
EPS (TTM):
-$0.53
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Odyssey Marine Exploration has 509.76% upside to fair value with a price target of -- per share.
OMEX vs. S&P 500
-
Over the past 5 trading days, Odyssey Marine Exploration has underperformed the S&P 500 by -8.16% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Odyssey Marine Exploration does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Odyssey Marine Exploration revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Odyssey Marine Exploration reported revenues of $213.9K.
Earnings Growth
-
Odyssey Marine Exploration has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Odyssey Marine Exploration reported earnings per share of $0.13.
Enterprise value:
-8.8M
EV / Invested capital:
--
Price / LTM sales:
43.25x
EV / EBIT:
-0.69x
EV / Revenue:
-11.48x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-15.82x
Price / Operating cash flow:
59.58x
Enterprise value / EBITDA:
-0.68x
Gross Profit (TTM):
-$3.2M
Return On Assets:
54.44%
Net Income Margin (TTM):
-1321.66%
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
-1340.88%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $1.3M | $803.8K | $768.7K | $166.6K | $136.2K | |
| Gross Profit | -$8.4M | -$3.5M | -$2.3M | -$568.9K | $292.9K | |
| Operating Income | -$17.9M | -$10.3M | -$12M | -$2.2M | -$1.4M | |
| EBITDA | -$27.3M | $1.6M | $13M | -$9.2M | -$6M | |
| Diluted EPS | -$1.32 | $0.27 | -$1.06 | -$0.41 | -$0.94 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $6.9M | $3.3M | $4M | $4.9M | $5.8M | |
| Total Assets | $11.8M | $8.9M | $13.9M | $22.8M | $18.5M | |
| Current Liabilities | $53.9M | $52.6M | $41.8M | $31.5M | $22.5M | |
| Total Liabilities | $69.7M | $71.4M | $102.5M | $108.7M | $97.6M | |
| Total Equity | -$57.9M | -$62.5M | -$88.7M | -$85.9M | -$79.1M | |
| Total Debt | $42.6M | $41.9M | $22.4M | $23.3M | $22.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$10.2M | -$10.2M | $642.3K | -$1.4M | -$1.8M | |
| Cash From Investing | -$2.5M | -$1M | -$84.4K | -$599.6K | $4K | |
| Cash From Financing | $11.9M | $13.8M | $212K | $5.5M | $3.7M | |
| Free Cash Flow | -$11.7M | -$11.5M | $558K | -$2.2M | -$1.8M | |
OMEX
Sector
Market Cap
$35.9M
$585.2M
Price % of 52-Week High
22.07%
73.78%
Dividend Yield
0%
0%
Shareholder Yield
--
2.4%
1-Year Price Total Return
-66.3%
-7.27%
Beta (5-Year)
-0.767
0.781
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.27
200-day SMA
Sell
Level
$1.39
Bollinger Bands (100)
Buy
Level
0.29 - 0.79
Chaikin Money Flow
Sell
Level
-41.8M
20-day SMA
Buy
Level
$0.75
Relative Strength Index (RSI14)
Buy
Level
63.31
ADX Line
Buy
Level
43.61
Williams %R
Neutral
Level
-50.5882
50-day SMA
Buy
Level
$0.55
MACD (12, 26)
Buy
Level
0.23
25-day Aroon Oscillator
Buy
Level
56
On Balance Volume
Neutral
Level
890M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-19.8687)
Sell
CA Score
(Annual)
Level (-5.3804)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (30.4141)
Buy
Piotroski F Score
(Annual)
Level (7)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Odyssey Marine Exploration Inc is a deep-ocean exploration company. The company provides specialized mineral exploration, project development, and marine services to clients. It is engaged in the discovery, validation, and development of subsea mineral deposits in a socially and environmentally responsible manner. The company works with governments to identify mineral resources in Exclusive Economic Zones, focusing on phosphorite (fertilizer) and polymetallic nodules (battery metals) projects. Its projects include the ExO Phosphate project, CIC, Ocean Minerals, and the LIHIR Gold project.
Stock Forecast FAQ
In the current month, OMEX has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The OMEX average analyst price target in the past 3 months is --.
-
Where Will Odyssey Marine Exploration Stock Be In 1 Year?
According to analysts, the consensus estimate is that Odyssey Marine Exploration share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Odyssey Marine Exploration?
Analysts are divided on their view about Odyssey Marine Exploration share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Odyssey Marine Exploration is a Sell and believe this share price will drop from its current level to --.
-
What Is Odyssey Marine Exploration's Price Target?
The price target for Odyssey Marine Exploration over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is OMEX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Odyssey Marine Exploration is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of OMEX?
You can purchase shares of Odyssey Marine Exploration via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Odyssey Marine Exploration shares.
-
What Is The Odyssey Marine Exploration Share Price Today?
Odyssey Marine Exploration was last trading at $1.17 per share. This represents the most recent stock quote for Odyssey Marine Exploration. Yesterday, Odyssey Marine Exploration closed at $1.23 per share.
-
How To Buy Odyssey Marine Exploration Stock Online?
In order to purchase Odyssey Marine Exploration stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Shopify Stock Still a Buy in 2025 or Has Growth Peaked?
The big picture trends in e‑commerce sales are clearly in…
Is RTX The Best Growth Stock?
Among the worldwide aerospace and defense markets, the US controls…
Stock Ideas
Buy
71
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
63
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Buy
60
RGC alert for May 6
Regencell Bioscience Holdings [RGC] is up 113.25% over the past day.
Buy
63
SKX alert for May 6
Skechers USA [SKX] is down 0.02% over the past day.
Sell
20
PTCT alert for May 6
PTC Therapeutics [PTCT] is down 10.85% over the past day.
